- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Signifor, Signifor LAR
Synonyms :
pasireotide
Class :
Antineoplastic agents & Somatostatin analog
ADVERTISEMENT
Brand Name :
Signifor, Signifor LAR
Synonyms :
pasireotide
Class :
Antineoplastic agents & Somatostatin analog
Dosage Forms & Strengths
Solution, Subcutaneous (as diaspartate) (SC):
0.3 mg/ml (1ml)
0.6 mg/ml (1ml)
0.9 mg/ml (1ml)
Suspension, Intramuscular (as pamoate) (IM):
10mg/vial
30mg/vial
20mg/vial
40mg/vial
60mg/vial
Note: Monitor patients with diabetes mellitus and optimize antidiabetic therapy prior to initiating therapy. Treat the patients with hypokalemia and hypomagnesemia before starting the therapy.
Initial IM dose:
40
mg
once every 4 weeks (dose can be adjusted according to levels of growth hormone to 60 mg once every 4 weeks after >3 months if levels are normalized. Decrease the dose to 20 mg if adverse effects occur.)
Do not administer missed dose 2 weeks prior to the next dose.
Initial SC:
0.6 - 0.9
mg
twice a day
Dose adjustment: Increase the dose in increments of 0.3 mg twice a day every 3 months depending on the normalization of urinary-free cortisol levels
Decrease the dose by 0.3 mg if an adverse reaction occurs
Maintenance dose SC: 0.3 to 0.9 mg twice a day
Initial IM: 10 mg once every 4 weeks
Dose adjustment: Monitor for 24-hour UFC levels, if not normalized increase the dose maximum up to 40 mg once every 4 weeks
Discontinue the therapy if adverse reactions occur
Do not administer missed dose 2 weeks prior to the next dose
Dose Adjustments
For Hepatotoxicity:
Moderate hepatotoxicity for IM dose: Initially 20 mg once every 4 weeks and maintain not more than 40 mg once every 4 weeks
Severe hepatic impairment for IM dose: Discontinue temporarily
Moderate hepatotoxicity for SC: initial 0.3 mg twice a day and maintain 0.6 mg twice a day
Severe hepatic impairment for SC dose: Discontinue temporarily
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
QTc interval is increased both by lenvatinib and pasireotide
when both drugs are combined may enhance the bradycardia effect and raise blood pressure
when both drugs are combined may enhance the bradycardia effect and raise blood pressure
when both drugs are combined may enhance the bradycardia effect and raise blood pressure
when both drugs are combined may enhance the bradycardia effect and raise blood pressure
when both drugs are combined may enhance the bradycardia effect and raise blood pressure
It may diminish the effects when combined with copper CU 64 dotatate by the receptor binding mechanism
pasireotide exerts its influence on gallium ga 68 dotatate by engaging in receptor binding competition, thereby diminishing its effects
Frequency defined:
>10%:
Peripheral edema
Hypertension
Alopecia
Diabetes Mellitus
Abdominal distension
Decreased appetite
Prolonged partial thromboplastin time
Influenza
Anxiety
Fatigue
Insomnia
Asthenia
Back pain
Nasopharyngitis
1%-10%
Prolonged QT interval on ECG
Sinus brady cardia
Pruritis
Hypokalemia
Hypothyroidism
Weight loss
Cholecystitis
Anemia
Dizziness
Cough
<1%:
Diabetic ketoacidosis
Bradycardia
Cholangitis
Increased serum bilirubin
Pregnancy consideration: insufficient information available regarding its effect on pregnancy to recommend its use.
Lactation: excretion of pasireotide in breast milk is not known.
Pregnancy category:
Patient information leaflet
Generic Name: Pasireotide
Pronounced: pas-ree-tide
Why do we use pasireotide?
Pasireotide is a somatostatin analog class of antineoplastic drug. It is used to treat Cushing’s disease and acromegaly.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
